Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Idexx Laboratories (IDXX)

Nasdaq Health Care Health Care Equipment S&P 500Nasdaq-100
$676.04
+5.33 (+0.79%)
Close of Nov 06, 2026 · end-of-day data
Next earnings date
Not scheduled yet
No report date announced in the next three weeks.
Consensus EPS estimate
—
Shown once a date is announced.
Last report (Nov 02)
$3.98 vs $3.71 est.
Surprise +7.3%

Earnings surprise history

reported EPS vs consensus
ReportedQuarterEPS estimateReported EPSSurprise
Nov 02, 2026Sep/2026$3.71$3.98+7.3%

Our record of IDXX's reports since we began tracking; it grows each quarter.

Latest results, in brief

All IDXX 8-K briefs →
Nov 2, 6:30 AM ET

IDEXX Reports Q3 Revenue of $1.2B and Raises Full-Year 2026 Guidance

Positive earnings 2.02

IDEXX Laboratories announced third-quarter revenue of $1,214 million and diluted earnings per share of $4.01, representing solid year-over-year gains. Driven by strong Companion Animal Group performance and innovation adoption, the company raised its full-year 2026 revenue and EPS outlook for shareholders.

  • Third-quarter revenue reached $1,214 million, up 10% as reported and organic.
  • Diluted earnings per share were $4.01, an increase of 18% as reported.
  • Full-year 2026 revenue guidance was updated to a range of $4,741 million to $4,767 million.
  • Full-year 2026 EPS outlook was raised to $14.96 to $15.16.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Quarterly results

Full financial statements →
Quarter endedRevenueYoYEPS (diluted)YoYNet incomeNet margin
Sep 2026$1.21B+9.9% $4.01+17.9% $317.14M26.1%
Jun 2026$1.22B+9.7% $4.27+17.6% $338.41M27.8%
Mar 2026$1.14B+14.3% $3.47+17.2% $278.45M24.4%
Dec 2025$1.09B+14.3% $3.09+17.9% $248.19M22.8%
Sep 2025$1.11B+13.3% $3.40+21.4% $274.61M24.8%
Jun 2025$1.11B+10.6% $3.63+48.8% $293.99M26.5%
Mar 2025$998.43M+3.6% $2.96+5.3% $242.68M24.3%
Dec 2024$954.29M+5.8% $2.62+13.4% $216.15M22.7%

From Idexx Laboratories's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.

Annual results

Fiscal yearRevenueGrowthEPS (diluted)GrowthNet margin
FY2025$4.30B+10.4% $13.08+22.6%24.6%
FY2024$3.90B+6.5% $10.67+6.1%22.8%
FY2023$3.66B+8.7% $10.06+25.3%23.1%
FY2022$3.37B+4.7% $8.03-6.6%20.2%
FY2021$3.22B+18.8% $8.60+28.2%23.2%

Frequently asked questions

When is Idexx Laboratories's next earnings date?

Idexx Laboratories has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.

What did Idexx Laboratories earn last quarter?

For the quarter ended Sep 2026, Idexx Laboratories reported diluted EPS of $4.01 (+17.9% year over year) on revenue of $1.21B (+9.9%).

Where do these numbers come from?

Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.

Not investment advice. Figures can be restated by the company in later filings.